COPENHAGEN, Aug 19 (Reuters) - Denmark’s Novo Nordisk said it has seen no evidence of a statistically significant increase in cases of pancreas inflammation in trials of drug candidate liraglutide. The U.S. Food and Drug Administration warned on Monday of more cases of dangerous pancreas inflammation in patients taking Amylin Pharmaceuticals Inc’s diabetes drug, Byetta, a drug that is expected to compete with liraglutide [ID:nN18460095].
